Medroxyprogesterone Acetate
-
Subject Areas on Research
- A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
- Adolescent satisfaction with postpartum contraception and body weight concerns.
- Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
- Contraceptive Methods and the Impact of Menstruation on Daily Functioning in Women with Sickle Cell Disease.
- Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
- Differences in brain volumes among males and female hormone-therapy users and nonusers.
- Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women.
- Hormone therapy: physiological complexity belies therapeutic simplicity.
- Progestins Inhibit Tumor Necrosis Factor α-Induced Matrix Metalloproteinase 9 Activity via the Glucocorticoid Receptor in Primary Amnion Epithelial Cells.
- Retinal venous occlusion associated with depot medroxyprogesterone acetate.
- Smelling wrong: hormonal contraception in lemurs alters critical female odour cues.
- Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS).
- The Effect of Progestins on Tumor Necrosis Factor α-Induced Matrix Metalloproteinase-9 Activity and Gene Expression in Human Primary Amnion and Chorion Cells In Vitro.
- The impact of short-term depot-medroxyprogesterone acetate treatment on resting metabolic rate.